Drug Trial Radar · NCT04072835
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Last checked: Nov 20, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,116
Actual
Start
Sep 23, 2019
Primary completion
Jan 26, 2023
Study completion Jan 26, 2023
Sponsor
- Lead sponsor
- Milestone Pharmaceuticals Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- IQVIA Biotech
- First posted
- Aug 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NODE-303 was a multi-center, open label study to evaluate the safety of etripamil NS in participants with Paroxysmal Supraventricular Tachycardia (PSVT). Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when they felt the onset of PSVT symptoms. Participants self-administered etripamil NS if vagal maneuver was ineffective. After an episode of PSVT where study drug was administered, the participant returned to the investigative site and had the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
Conditions
- Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NSDrug
Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting.Time frame: From Baseline until a maximum of 4 episodes of perceived PSVT are treated with study drug, up to a maximum duration of 40 months.
Locations
124 sites in 5 countries. Site status is shown where the registry gives one.
1077
Gilbert, Arizona
1121
Fremont, California
1035
Stanford, California
1023
Vista, California
1083
West Hills, California
101
Littleton, Colorado
1010
Bridgeport, Connecticut
1066
Trumbull, Connecticut
1042
Bradenton, Florida
1106
Daytona Beach, Florida
1107
Edgewater, Florida
1032
Hialeah, Florida
1026
Miami, Florida
1055
Miami, Florida
1064
Naples, Florida
1071
North Miami Beach, Florida
1009
Orlando, Florida
1060
Saint Augustine, Florida
1022
Cumming, Georgia
137
Macon, Georgia
1115
Coeur d'Alene, Idaho
1045
Peoria, Illinois
149
Fort Wayne, Indiana
1025
West Des Moines, Iowa
1008
Monroe, Louisiana
1007
Salisbury, Maryland
1078
Boston, Massachusetts
166
Lansing, Michigan
119
Rochester, Minnesota
1093
Saint Paul, Minnesota
1099
Kansas City, Missouri
1134
Elmer, New Jersey
1133
Haddon Heights, New Jersey
114
New York, New York
1021
Southampton, New York
129
Charlotte, North Carolina
1065
Charlotte, North Carolina
1079
Mount Airy, North Carolina
1018
Statesville, North Carolina
1024
Canton, Ohio
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.